1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
BriaPro Therapeutics, a subsidiary of BriaCell Therapeutics, filed unaudited financial statements for the three and nine months ended April 30, 2026, with Canadian regulators. The nine-month net loss rose to $712,236 from $519,804 a year earlier, and the filing states a material uncertainty about the company's ability to continue as a going concern, with BriaCell as its only stated financing source until it raises more capital.
Nine-month net loss of $712,236 versus $519,804 for the same period a year earlier; three-month net loss narrowed to $240,005 from $286,619
Cash of $299,950 at April 30, 2026, including a $300,000 related-party advance from BriaCell; negative working capital of $1,937,495
Amounts owed to BriaCell group companies totaled $2,093,345; the monthly service fee was reduced from $20,000 to $5,000 effective April 30, 2026
On March 31, 2026, the company acquired the sCD80 license from BriaCell for 23,972,589 common shares valued at $846,532
Worthington Enterprises reported fourth-quarter fiscal 2026 results for the quarter ended May 31, 2026, with net sales up 17% to $371 million, driven largely by acquisitions, while adjusted EBITDA fell to $83.5 million from $85.1 million. For the full fiscal year, adjusted EBITDA rose 12% to $296 million and adjusted earnings per share rose 9% to $3.37. The company also disclosed a June 22, 2026 retention award of 25,000 performance shares each to its chief financial officer, general counsel and two segment presidents.
Q4 net sales were $371 million, up 17% from $318 million; organic growth was 3%.
Q4 adjusted EBITDA was $83.5 million versus $85.1 million a year earlier; adjusted earnings were $0.97 per share versus $1.06.
Full-year fiscal 2026 adjusted EBITDA rose 12% to $296 million; net debt was $278 million at May 31, 2026.
On June 22, 2026, the compensation committee awarded 25,000 performance shares each to Colin J. Souza (CFO), Patrick J. Kennedy, Steven M. Caravati and James R. Bowes.
Apogee Enterprises reported first-quarter fiscal 2027 results, with net sales down 1.1% to $342.7 million on lower volume, while diluted earnings per share swung to $0.54 from a loss of $0.13 a year earlier. The company reaffirmed its fiscal 2027 guidance and said the pending Kalwall acquisition remains on track for an early July close.
Net sales were $342.7 million, down 1.1% from $346.6 million, driven by lower volume partly offset by favorable pricing.
Diluted EPS was $0.54 versus a loss of $0.13; adjusted diluted EPS was $0.57 versus $0.56.
Adjusted EBITDA fell 6.6% to $32.1 million, and adjusted EBITDA margin declined to 9.4% from 9.9%.
Fiscal 2027 guidance was reaffirmed: net sales of $1.38 billion to $1.43 billion and adjusted diluted EPS of $2.70 to $3.25, excluding Kalwall.
Cineverse reported fourth-quarter revenue of $26.0 million, up 67% from a year earlier, largely from the Giant Worldwide and IndiCue acquisitions, which contributed $11.6 million in their first partial quarter. For the full fiscal year ended March 31, 2026, revenue fell 16% to $65.7 million and the company posted a net loss attributable to common stockholders of $9.2 million, or $0.49 per diluted share, compared with net income of $3.2 million, or $0.16 per diluted share, a year earlier. The company reaffirmed its fiscal 2027 guidance of $115 million to $120 million in revenue and $10 million to $20 million in Adjusted EBITDA.
Q4 FY 2026 revenue of $26.0 million versus $15.6 million in Q4 FY 2025; Q4 net income attributable to common stockholders of $1.1 million, or $0.05 per diluted share
FY 2026 revenue of $65.7 million versus $78.2 million, with the decline tied to the prior-year Terrifier 3 comparison
FY 2026 net loss attributable to common stockholders of $(9.2) million, or $(0.49) per diluted share, versus net income of $3.2 million in FY 2025; Adjusted EBITDA of $(3.4) million versus $13.9 million
Fiscal 2027 guidance reaffirmed: revenue of $115 million to $120 million and Adjusted EBITDA of $10 million to $20 million; cash and cash equivalents were $3.4 million as of March 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.